Sign In
Buy AXS
$94.55
-0.89 (-0.93%)
At Close: Jun 03, 2026
Why Axis Capital (AXS) is a Top Value Stock for the Long-Term
10:46am, Wednesday, 29'th Jan 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Axis Capital (AXS) is a Strong Momentum Stock
10:50am, Tuesday, 28'th Jan 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Earnings Preview: Axis Capital (AXS) Q4 Earnings Expected to Decline
11:06am, Wednesday, 22'nd Jan 2025
Axis Capital (AXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXIS Capital to Release Fourth Quarter Financial Results on January 29, 2025
04:15pm, Monday, 06'th Jan 2025
PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited (“AXIS Capital” or the “Company”) (NYSE: AXS) today announced that it expects to release financial results
Sara Farrup Becomes AXIS Head of Global Markets
08:45am, Monday, 06'th Jan 2025
PEMBROKE, Bermuda--(BUSINESS WIRE)--AXIS Capital Holdings Limited (“AXIS Capital” or “AXIS” or the “Company”) (NYSE: AXS) today announced Sara Farrup (nee Mitchell) has assumed the role of
AXS Rallies 58.5% in a Year: A Signal for Investors to Hold Tight?
11:10am, Friday, 03'rd Jan 2025
AXIS Capital stock rallies on the back of well-performing specialty insurance, reinsurance as well as the accident and health portfolio.
Will Axis Capital (AXS) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Thursday, 02'nd Jan 2025
Axis Capital (AXS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
09:15am, Tuesday, 31'st Dec 2024
Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AX
ACCORD-2 Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)
Here's Why Axis Capital (AXS) is a Strong Value Stock
10:46am, Thursday, 26'th Dec 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 P&C Insurance Stocks That Have Gained More Than 50% in 2024
11:21am, Tuesday, 24'th Dec 2024
Despite higher catastrophe losses, MCY, AXS and PLMR not only outperforms the industry but also crushes the Zacks S&P 500 composite and the Finance sector.
AXIS Capital: A Niche Leader Priced For NOPAT Fall
09:00pm, Sunday, 22'nd Dec 2024
AXIS Capital is a global leader in specialty insurance and reinsurance, with a 30.2% annual NOPAT growth and a 15.3% ROIC in TTM. The company's diversified portfolio, disciplined risk management, and
PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited (“AXIS Capital” or “AXIS” or “the Company”) (NYSE: AXS) and Enstar Group Limited (“Enstar”) (Nasda
Why Axis Capital (AXS) is a Top Momentum Stock for the Long-Term
10:55am, Thursday, 12'th Dec 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AXIS President and CEO Vince Tizzio and CFO Pete Vogt to Speak at the 2024 UBS Global Specialty Insurance/Reinsurance Virtual Conference
04:15pm, Wednesday, 11'th Dec 2024
PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited ("AXIS Capital" or the “Company”) (NYSE: AXS) today announced that its President and CEO Vince Tizzio and CFO
